Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a

Arbutus BiopharmaApr 18 00:00 ET

Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge

A Delaware District Court sided with Arbutus Biopharma Corporation (NASDAQ:ABUS) and Genevant Sciences in their ongoing patent infringement case against Moderna Inc (NASDAQ:MRNA) COVID-19 vaccine.The

BenzingaApr 4 14:32 ET

Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead

Moderna Inc (NASDAQ:MRNA) stock closed lower by 2.32% on Wednesday, as news around Arbutus Biopharma (NASDAQ:ABUS) impacted investor sentiment. Arbutus has received permission to pursue its patent inf

BenzingaApr 4 09:34 ET

Express News | JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $4 Price Target

Moomoo 24/7Apr 4 08:49 ET

Unpleasant Surprises Could Be In Store For Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares

You may think that with a price-to-sales (or "P/S") ratio of 28.9x Arbutus Biopharma Corporation (NASDAQ:ABUS) is a stock to avoid completely, seeing as almost half of all the Biotechs companies in th

Simply Wall StApr 4 06:13 ET

Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)

TipRanksApr 3 15:20 ET